Markets:

Overview

News

Currencies

International

Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

499.07 +2.10 (+0.42%)

Streaming Delayed Price Updated: 9:40 AM EST, Jan 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Here's How Much You Would Have Made Owning Madrigal Pharmaceuticals Stock In The Last 5 Years ↗

January 09, 2023

Via Benzinga

CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks ↗

January 06, 2023

Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.

Via Investor's Business Daily

5 Most Expensive Health Care Stocks You Should Worry About ↗

January 03, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Why These 7 Healthcare Stocks Could Soar in 2023 ↗

January 02, 2023

These healthcare stocks to buy are trading at a hefty discount and are poised to deliver robust returns in 2023.

Via InvestorPlace

5 Top Stocks for January ↗

January 01, 2023

Now is the time to begin crafting your watch list for 2023.

Via The Motley Fool

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,800 Today ↗

December 23, 2022

Via Benzinga

Analyst Ratings for Madrigal Pharmaceuticals ↗

December 20, 2022

Via Benzinga

Singing Machine, Blue Apron, Camber Energy And More Short Squeeze Candidates That Could Soar This Week ↗

December 27, 2022

Potential short squeeze plays gained steam in 2021 and have continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common...

Via Benzinga

This Stock That Tripled in 2022 Could Rocket Even Higher in 2023 ↗

December 26, 2022

Potential suitors with heaps of cash to spend are lining up to get a closer look at this company's results.

Via The Motley Fool

Stock Market Falls Sharply Again As Tesla Dives, Micron Hits Chips; Nike, FedEx Strong: Weekly Review ↗

December 23, 2022

The market uptrend is under pressure.

Via Investor's Business Daily

Universal Health Services, Madrigal Pharmaceuticals And These Overbought Majors In The Healthcare Sector ↗

December 23, 2022

The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Why Madrigal Pharmaceuticals Was a Top Stock This Week ↗

December 23, 2022

Biotech bulls stampeded the company following its latest clinical update.

Via The Motley Fool

7 Drug Stocks That Will Soar in 2023 ↗

December 22, 2022

These drug stocks to buy look poised to generate huge profits for investors in 2023 and in subsequent years.

Via InvestorPlace

Earnings Optimism Puts Wind In Wall Street's Sails ↗

December 21, 2022

The major indexes are extending their rally off a mid-December losing streak.

Via Talk Markets

Why Did Viking Therapeutics Stock Skyrocket

December 21, 2022

VKTX stock is young but strong and they have excellent potential, particularly following successful trial results from Madrigal Pharma's recent drug trial.

Via MarketBeat

Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says ↗

December 20, 2022

Via Benzinga

Madrigal Pharmaceuticals Gets Price Target Bumps By Analysts Following Successful NASH Study ↗

December 20, 2022

Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) announced positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy trial of resmetirom. Madrigal Pharmaceuticals shares jumped 268.1% to close...

Via Benzinga

Peering Into Madrigal Pharmaceuticals's Recent Short Interest ↗

December 20, 2022

Madrigal Pharmaceuticals's (NASDAQ:MDGL) short percent of float has risen 3.82% since its last report. The company recently reported that it has 2.16 million shares sold short, which is 15.49% of all...

Via Benzinga

Tesla To $285? Here Are 10 Other Price Target Changes For Tuesday ↗

December 20, 2022

Wells Fargo raised Ross Stores, Inc. (NASDAQ: ROST) price target from $120 to $135. Wells Fargo analyst Ike Boruchow maintained an Overweight rating on the stock. Ross Stores shares fell 0.9% to close...

Via Benzinga

Here's How An Options Trader Made $5.5 Million In One Day ↗

December 20, 2022

Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) shares rose sharply on Monday after the company announced positive topline results from the pivotal Phase 3 MAESTRO-NASH (fatty liver disease)

Via Benzinga

Tesla, Amazon, Apple, Madrigal, Walt Disney: Why These 5 Stocks Are Drawing Investors' Attention Today ↗

December 19, 2022

Major Wall Street indices closed in the red on Monday as investor optimism on the much-anticipated Santa Claus rally began to fade over fears of recession gaining momentum.

Via Benzinga

Healthcare Portfolio Is Doing Well But Biotech Stocks Are Mired In Macro ↗

December 19, 2022

The biotech sector has not done well in 2022 despite some strong runs. Small and mid-cap stocks are more “risk-off’ with interest rates rising and sentiment waning.

Via Talk Markets

Madrigal Pharmaceuticals (NASDAQ: MDGL) Reports Impressive Topline Results from Phase 3 Trial of Resmetirom to Treat NASH and Liver Fibrosis

December 19, 2022

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development

Via Spotlight Growth

Dow Struggles To Maintain Morning Gains ↗

December 19, 2022

This morning's rally was short-lived, and by midday, the major indexes were trading back in the red amid looming recession anxieties.

Via Talk Markets

12 Health Care Stocks Moving In Monday's Intraday Session ↗

December 19, 2022

Via Benzinga

Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session ↗

December 19, 2022

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.

Via Benzinga

Why Madrigal Pharmaceuticals Stock Is Crushing It Today ↗

December 19, 2022

The company reported stellar late-stage clinical trial results for its experimental NASH (nonalcoholic steatohepatitis) drug.

Via The Motley Fool

Madrigal Pharmaceuticals, Cerevel Therapeutics And Some Other Big Stocks Moving Higher On Monday ↗

December 19, 2022

U.S. stocks traded mixed, with the Nasdaq Composite dropping around 90 points on Monday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Tesla's Bouncing, but This Nasdaq Stock Tripled Monday Morning ↗

December 19, 2022

Good news can come in different forms.

Via The Motley Fool

Why Is Viking Therapeutics (VKTX) Stock Up 67% Today? ↗

December 19, 2022

Viking Therapeutics (VKTX) stock is taking off on Monday with heavy trading without any news from the biopharmaceutical company.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.